Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, May 12, 2020
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Matthew Luchini Maintained (BLUE) at Buy with Increased Target to $112 on, May 12th, 2020
Matthew Luchini of BMO Capital, Maintained "bluebird bio, Inc." (BLUE) at Buy with Increased Target from $107 to $112 on, May 12th, 2020.
Matthew has made no other calls on BLUE in the last 4 months.
There are 3 other peers that have a rating on BLUE. Out of the 3 peers that are also analyzing BLUE, 1 agrees with Matthew's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Matthew Harrison of "Morgan Stanley" Maintained at Hold with Decreased Target to $69 on, Wednesday, April 15th, 2020
These are the ratings of the 2 analyists that currently disagree with Matthew
- Benjamin Burnett of "Stifel" Upgraded from Hold to Strong Buy and Decreased Target to $70 on, Friday, March 27th, 2020
- Joshua Schimmer of "Evercore ISI Group" Upgraded from Hold to Buy and Increased Target to $100 on, Monday, February 3rd, 2020
